Fospropofol disodium: Anesthetic drug

Drugs of the Future

Volumn 31, Issue 10, 2006, Pages 859-863

  Revill, P ^a   Serradell, N ^a   Bolos J ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAVAN; FENTANYL; FOSPROPOFOL DISODIUM; GPI 15715; MIDAZOLAM; PQ 1002; PROPOFOL; UNCLASSIFIED DRUG;

APNEA; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BURNING SENSATION; CLINICAL TRIAL; COLONOSCOPY; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; HEART RATE; HUMAN; HYPERLIPIDEMIA; PAIN; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 33846055422     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.10.1038240     Document Type: Article

References (32)

1. Stella, V.J., Zygmunt, J.J., Georg, I.G., Safadi, M.S. (University of Kansas). Water soluble prodrugs of hindered alcohols. CA 2339834, EP 1102776, US 6204257, WO 0008033.
2. Bonneville, G., Delahanty, G., Walz, A.J. (Guilford Pharmaceuticals Inc.). Process for preparing water-soluble phosphonooxymethyl derivs. of alcohol and phenol. JP 2005514431, WO 03059255.
3. Bryson, H.M., Fulton, B.R., Faulds, D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995, 50(3): 513-59.
4. Kanto, J., Gepts, E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet 1989, 17(5): 308-26.
5. Nakane, M., Iwama, H. A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. Br J Anaesth 1999, 83(3): 397-404.
6. Lindholm, M. Critically ill patients and fat emulsions. Minerva Anestesiol 1992, 58(10): 875-9.
7. Kelbel, I., Koch, T., Weber, A., Schiefer, H.G., van Ackern, K., Neuhof, H. Alterations of bacterial clearance induced by propofol. Acta Anaesthesiol Scand 1999, 43(1): 71-6.
8. Doursout, M.F., Joseph, P.M., Liang, Y.Y., Hartley, C.J., Chelly, J.E. Role of propofol and its solvent, Intralipid, in nitric oxide-induced peripheral vasodilatation in dogs. Br J Anaesth 2002, 89(3): 492-8.
9. Marik, P.E. Propofol: Therapeutic indications and side-effects. Curr Pharm Des 2004, 10(29): 3639-49.
10. Boucher, B.A., Feler, CA, Dean, J.C. et al. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy 1996, 16(4): 638-45.
11. Browne, T.R., Kugler, A.R., Eldon, M.A. Pharmacology and pharmacokinetics of fosphenytoin. Neurology 1996, 46: S3-7.
12. Schywalsky, M., Ihmsen, H., Tzabazis, A. et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol 2003, 20(3): 182-90.
13. Rechner, J., Ihmsen, H., Hatterscheid, D. et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003, 99(2): 303-13.
14. Fechner, J., Ihmsen, H., Hatterscheid, D. et al. Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 2004, 101(3): 626-39.
15. Fechner, J., Ihmsen, H., Jeleazcov, C., Vornov, J., Schwilden, H., Schuttler, J. Pharmacokinetics and pharmacodynamics of GPI 15715 - a water soluble propofol prodrug - compared to propofol. Naunyn-Schmied Arch Pharmacol 2004, 369(Suppl. 1): Abst 591.
16. Gibiansky, E., Struys, M.M., Gibiansky, L. et al. AQUAVAN® injection, a water-soluble prodrug of propofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN® (part 1): Pharmacokinetics. Anesthesiology 2005, 103(4): 718-29.
17. Fechner, J., Ihmsen, H., Schiessl, C. et al. Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers. Anesth Analg 2005, 100(3): 701-6.
18. Fechner, J., Ihmsen, H., Burak, E., Vornov, J., Schwilden, H. Target controlled infusion (TCI) of Aquavan™, a water soluble prodrug of propofol, for conscious sedation in volunteers. Anesthesiology 2002, 96: Abst A-438.
19. Struys, M.M., Vanluchene, A.L., Gibiansky, E. et al. AQUAVAN® injection, a water-soluble prodrug of propofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN® (part 2): Pharmacodynamics and safety. Anesthesiology 2005, 103(4): 730-43.
20. Vanluchene, A.L., Van Bortel, L., Vornov, J., Burak, E., Struys, M.M. Pharmacodynamics of AQUAVAN™ Injection, a water-soluble prodrug of propofol as a bolus injection: A phase I dose escalation comparison with DIPRIVAN®. Anesthesiology 2002, 96: Abst A-455.
21. Gibiansky, E., Gibiansky, L. Population PK/PD model of GPI 15715 and GPI-derived propofol in sedation and comparison of PK/PD models for ordered categorical observations. 14th Meet Popul Approach Group Eur (June 16-17, Pamplona) 2005, Abst P-15.
22. Gibiansky, E., Gibiansky, L. Population pharmacokinetic/ pharmacodynamic model of GPI 15715 and GPI-derived propofol in sedation and comparison of models for OAA/s scores. Annu Meet Am Soc Anesthesiol (ASA) (Oct 22-26, Atlanta) 2005, Abst A776.
23. Gibiansky, E., Gibiansky, L., Enriquez, J. Population pharmacokinetic model of sedative doses of GPI 15715 and propofol liberated from GPI 15715. Clin Pharmacol Ther [Annu Meet Am Soc Clin Pharmacol Ther (ASCPT) (March 2-6, Orlando) 2005] 2005, 77(2): Abst PI-154.
24. Gibiansky, E., Gibiansky, L. Population pharmacokinetic models for predicting sedation with GPI 15715 prodrug of propofol (AQUAVAN® Injection) for colonoscopy. Am J Gastroenterol [70th Annu Sci Meet Am Coll Gastroenterol (Oct 28-Nov 2, Honolulu) 2005] 2005, 100(Suppl. 9): Abst 414.
25. Gibiansky, E., Gibiansky, L. Population pharmacokinetic/ pharmacodynamic model of GPI 15715 and GPI-derived propofol in sedation. Annu Meet Am Coll Clin Pharm (Oct 23-26, San Francisco) 2005, Abst 307E.
26. MGI Pharma provides update on Aquavan® injection program; top line results of successful phase 2 dose ranging study summarized: Aquavan™ injection pivotal program planned to begin in early 2006. MGI Pharma Press Release December 21, 2005.
27. Study of AQUAVAN® Injection (AQUAVAN; fospmpofol disodium) for sedation during colonoscopy (NCT00125424). ClinicalTrials.gov Web site 2006.
28. Cohen, L.B., Wang, C., Jones, J.B. AQUAVAN is safe and effective for minimal to moderate sedation during colonoscopy. Anesthesiology 2006, 105(Suppl.): Abst A1367.
29. MGI Pharma announces initiation of Aquavan® Injection pivotal program; patient enrollment expected to conclude by year-end. MGI Pharma Press Release March 20, 2006.
30. An effectiveness and safety study of AQUAVAN® Injection (fospmpofol disodium) for sedation during flexible bronchoscopy (NCT00306722). ClinicalTrials.gov Web site 2006.
31. An effectiveness and safety study of AQUAVAN® injection (fospropofol disodium) for sedation during colonoscopy (NCT00261599). ClinicalTrials.gov Web site 2006.
32. A safety study of AQUAVAN® (fospropofol disodium) Injection for sedation during minor surgical procedures (NCT00327392). ClinicalTrials.gov Web site 2006.